Archive

Research Area: Diabetes

Nut consumption and risk of type II diabetes in the Physicians’ Health Study.

Kochar, J., J.M. Gaziano, L. Djousse, 2010. Nut consumption and risk of type II diabetes in the Physicians’ Health Study. European Journal of Clinical Nutrition. 64:75–79.

Background/Objectives: While type II diabetes (DM) is a major cause of morbidity in the United States, limited data are available on the association between nut intake and incident DM. We sought to examine the association between nut consumption and the risk of DM. Subjects/Methods: Prospective cohort of 20 224 male participants of the Physicians’ Health Study I. Nut consumption was estimated using a 19-item brief food frequency questionnaire, and incident DM was ascertained through yearly follow-up questionnaires. Cox regression was used to estimate relative risks of DM. Results: The average age of the study participants was 54.4±9.4 years (range: 40.7–87.1). During a mean follow-up of 19.2 years, 1828 cases of DM occurred. The crude incidence rates of DM were 4.82, 4.85, 4.92, 4.16, 4.29 and 3.32 cases per 1000 person-years for individuals reporting nut consumption of rarely/never, <1, 1, 2–4, 5–6 and 7+ servings per week, respectively. While nut consumption was associated with a lower risk of DM in a model adjusted for age (P for tend 0.017), such relation was attenuated on additional control for other confounders (multivariable adjusted hazard ratios (95% confidence interval) for DM were 1.0 (reference), 1.06 (0.93–1.20), 1.10 (0.95–1.26), 0.97 (0.82–1.14), 0.99 (0.76–1.30) and 0.87 (0.61–1.24) from the lowest to the highest category of nut consumption, respectively (P for trend 0.99). No statistically significant association between nut consumption and DM was found in either lean or overweight/obese participants. Conclusions: Our data do not show an association between nut consumption and incident DM in US male physicians.

Almond consumption and cardiovascular risk factors in adults with prediabetes.

Wien, M., D. Bleich, M. Raghuwanshi, S. Gould-Forgerite, J. Gomes, L. Monahan-Couch, K. Oda, 2010. Almond consumption and cardiovascular risk factors in adults with prediabetes. Journal of the American College of Nutrition. 29(3):189–197.

Objective: The authors tested the hypothesis that in adults with prediabetes, an almond-enriched American Diabetes Association (ADA) diet improves measures of insulin sensitivity and other cardiovascular risk factors compared with an ADA nut-free diet. Methods: Design: Randomized parallel-group trial. Setting: Outpatient dietary counseling and blood analysis. Subjects: Sixty-five adult participants with prediabetes. Intervention: Sixteen weeks of dietary modification featuring an ADA diet containing 20% of energy from almonds (approximately 2 oz per day). Measures of Outcome: Outcomes included fasting glucose, insulin, total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides, TC:HDL-C, and HbA1c, which were measured at weeks 0, 8, and 16. Body weight, body mass index (BMI), waist circumference, blood pressure, and nutrient intake were measured at weeks 0, 4, 8, 12, and 16. Results: The almond-enriched intervention group exhibited greater reductions in insulin (-1.78 µU/ml vs. +1.47 µU/ml, P = 0.002), homeostasis model analysis for insulin resistance (-0.48 vs. +0.30, P = 0.007), and homeostasis model analysis for beta-cell function (-13.2 vs. +22.3, P = 0.001) compared with the nut-free control group. Clinically significant declines in LDL-C were found in the almond-enriched intervention group (-12.4 mg/dl vs. -0.4 mg/dl) as compared with the nut-free control group. No changes were observed in BMI (-0.4 vs. -0.7 kg/m2, P = 0.191), systolic blood pressure (-4.4 mm Hg vs. -3.5 mm Hg, P = 0.773), or for the other measured cardiovascular risk factors. Conclusions: An ADA diet consisting of 20% of calories as almonds over a 16-week period is effective in improving markers of insulin sensitivity and yields clinically significant improvements in LDL-C in adults with prediabetes.

Nuts, metabolic syndrome and diabetes.

Kendall, C.W.C., A.R. Josse, A. Esfahani, D. J. A. Jenkins, 2010. Nuts, metabolic syndrome and diabetes.  British Journal of Nutrition.  104(4): 465-473.

The ability of nuts to improve the blood lipid profile and reduce the risk of CHD is now well established. The interest that health effects of nuts have gained recently has brought the possible benefits of consuming nuts, such as improvement in the conditions of the metabolic syndrome, and their potential to prevent and control diabetes into focus. Results from cohort studies have associated nut consumption with a reduced risk of developing diabetes and CVD. However, few randomised controlled trials have assessed the effect of nuts on diabetes control, and those that have been undertaken have shown improvements in blood lipids but not in the glycaemic control. Diabetes agencies are increasingly recognising the importance of controlling postprandial glycaemia fluctuations. Acute feeding studies indicate that nuts have minimal effects on rising postprandial blood glucose levels when eaten alone, and diminish the postprandial glycaemic response when consumed with high-glycaemic index carbohydrate foods in both normoglycaemic and type 2 diabetic individuals. Nuts have a healthy nutritional profile, high in MUFA and PUFA, are a good source of vegetable protein and are rich in fibre, vitamins and minerals. Incorporation of nuts in the diet may therefore improve the overall nutritional quality of the diet. While more research is required to establish the ability of nuts to improve glycaemic control in the long run, early data indicate that the inclusion of nuts in the diets of individuals with diabetes and the metabolic syndrome is warranted, in view of their potential to reduce CHD risk.

Effects of walnut consumption on endothelial function in type 2 diabetics: a randomized, controlled, cross-over trial.

Ma, Y., V.Y. Njike, J. Millet, S. Dutta, K. Doughty, J.A. Treu, D.L. Katz, 2010. Effects of walnut consumption on endothelial function in type 2 diabetics: a randomized, controlled, cross-over trial. Diabetes Care. 33(2):227-32.

Objective: To determine the effects of daily walnut consumption on endothelial function, cardiovascular biomarkers, and anthropometric measures in type 2 diabetics. Methods: This study was a randomized, controlled, single-blind, cross-over trial. Twenty-four participants with type 2 diabetes (mean age 58 years; 14 women, 10 men) were randomly assigned to one of the two possible sequence permutations to receive an ad libitum diet enriched with 56 g (366 kcal) of walnuts per day and an ad libitum diet without walnuts for 8 weeks. Subjects underwent endothelial function testing (measured as flow-mediated dilatation or FMD) and assessment of cardiovascular biomarkers before and after each 8-week treatment phase. The primary outcome measure was the change in FMD after 8 weeks. Secondary outcome measures included changes in plasma lipids, HbA1c, fasting glucose, insulin sensitivity, and anthropometric measures. Results: Endothelial function significantly improved after consumption of a walnut-enriched ad libitum diet compared to an ad libitum diet without walnuts (2.2 ± 1.7 % vs. 1.2 ± 1.6 %; p=0.04). The walnut-enriched diet increased fasting serum glucose, lowered serum total cholesterol and low-density lipoprotein cholesterol from baseline (10.0 ± 20.5 mg/dL; p=0.04, -9.7 ± 14.5 mg/dL; p<0.01; and -7.7 ± 10 mg/dL; p<0.01 respectively), though these changes were not significant when compared to an ad libitum diet without walnuts. There were no significant changes in anthropometric measures, plasma HbA1c, and insulin sensitivity. Conclusions: A walnut-enriched ad libitum diet improves endothelium-dependent vasodilatation in type 2 diabetics, suggesting a potential reduction in overall cardiac ris

Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome.

Wu, H., A. Pan, Z. Yu, Q. Qi, L. Lu, G. Zhang, D. Yu, G. Zong, Y. Zhou, X. Chen, L. Tang, Y. Feng, H. Zhou, X. Chen, H. Li,W. Demark-Wahnefried, F.B. Hu, X. Lin, 2010. Lifestyle counseling and supplementation with flaxseed or walnuts influence the management of metabolic syndrome. J. Nutr. 140(11):1937-42. .

A healthy lifestyle may ameliorate metabolic syndrome (MetS); however, it remains unclear if incorporating nuts or seeds into lifestyle counseling (LC) has additional benefit. A 3-arm, randomized, controlled trial was conducted among 283 participants screened for MetS using the updated National Cholesterol Education Program Adult Treatment Panel III criteria for Asian Americans. Participants were assigned to a LC on the AHA guidelines, LC + flaxseed (30 g/d) (LCF), or LC + walnuts (30 g/d) (LCW) group. After the 12-wk intervention, the prevalence of MetS decreased significantly in all groups: -16.9% (LC), -20.2% (LCF), and -16.0% (LCW). The reversion rate of MetS, i.e. those no longer meeting the MetS criteria at 12 wk, was not significantly different among groups (LC group, 21.1%; LCF group, 26.6%; and LCW group, 25.5%). However, the reversion rate of central obesity was higher in the LCF (19.2%; P = 0.008) and LCW (16.0%; P = 0.04) groups than in the LC group (6.3%). Most of the metabolic variables (weight, waist circumference, serum glucose, total cholesterol, LDL cholesterol, apolipoprotein (Apo) B, ApoE, and blood pressure) were significantly reduced from baseline in all 3 groups. However, the severity of MetS, presented as the mean count of MetS components, was significantly reduced in the LCW group compared with the LC group among participants with confirmed MetS at baseline (P = 0.045). Our results suggest that a low-intensity lifestyle education program is effective in MetS management. Flaxseed and walnut supplementation may ameliorate central obesity. Further studies with larger sample sizes and of longer duration are needed to examine the role of these foods in the prevention and management of MetS.

Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes

Li, S.-C., Y.-H. Liu, W.-H. Chang, C.-M. Chen, C.-Y. O. Chen, J.-F. Liu. 2010. Almond consumption improved glycemic control and lipid profiles in patients with type 2 diabetes. Metabolism.doi:10.1016/j.metabol.2010.04.009.

Almond consumption is associated with ameliorations in obesity, hyperlipidemia, hypertension, and hyperglycemia. The hypothesis of this 12-week randomized crossover clinical trial was that almond consumption would improve glycemic control and decrease the risk for cardiovascular disease in 20 Chinese patients with type 2 diabetes mellitus (T2DM) (9 male, 11 female; 58 years old; body mass index, 26 kg/m(2)) with mild hyperlipidemia. After a 2-week run-in period, patients were assigned to either a control National Cholesterol Education Program step II diet (control diet) or an almond diet for 4 weeks, with a 2-week washout period between alternative diets. Almonds were added to the control diet to replace 20% of total daily calorie intake. Addition of approximately 60 g almonds per day increased dietary intakes of fiber, magnesium, polyunsaturated fatty acid, monounsaturated fatty acid, and vitamin E. Body fat determined with bioelectrical impedance analysis was significantly lower in patients consuming almonds (almonds vs control: 29.6% vs 30.4%). The almond diet enhanced plasma alpha-tocopherol level by a median 26.8% (95% confidence intervals, 15.1-36.6) compared with control diet. Furthermore, almond intake decreased total cholesterol, low-density lipoprotein cholesterol, and the ratio of low-density lipoprotein cholesterol to high-density lipoprotein cholesterol by 6.0% (1.6-9.4), 11.6% (2.8-19.1), and 9.7% (0.3-20.9), respectively. Plasma apolipoprotein (apo) B levels, apo B/apo A-1 ratio, and nonesterified fatty acid also decreased significantly by 15.6% (5.1-25.4), 17.4% (2.8-19.9), and 5.5% (3.0-14.4), respectively. Compared with subjects in the control diet, those in the almond diet had 4.1% (0.9-12.5), 0.8% (0.4-6.3), and 9.2% (4.4-13.2) lower levels of fasting insulin, fasting glucose, and homeostasis model assessment of insulin resistance index, respectively. Our results suggested that incorporation of almonds into a healthy diet has beneficial effects on adiposity, glycemic control, and the lipid profile, thereby potentially decreasing the risk for cardiovascular disease in patients with type 2 diabetes mellitus.

Health benefits of nuts in prevention and management of diabetes

Kendall, C.W.C., A. Esfahani, J. Truan, K. Srichaikul, D.J.A. Jenkins, 2010. Health benefits of nuts in prevention and management of diabetes. Asia Pac J Clin Nutr. 19(1):110-116.

The effects of tree nuts on risk factors for coronary heart disease (CHD), in particular blood lipids, have been investigated in a number of studies and the beneficial effects are now recognized. The beneficial effects of nuts on CHD in cohort studies have also been clearly demonstrated. However, while there is also reason to believe the unique micro- and macronutrient profiles of nuts may help to control blood glucose levels, relatively few studies have investigated their role in diabetes control and prevention. Nuts are low in available carbohydrate, have a healthy fatty acid profile, and are high in vegetable protein, fiber and magnesium. Acute feeding studies indicate that when eaten alone nuts have minimal effects on raising postprandial blood glucose levels. In addition, when nuts are consumed with carbohydrate rich foods, they blunt the postprandial glycemic response of the carbohydrate meal. Despite the success of these acute studies, only a limited number of trials have been conducted with nuts in type 2 diabetes. These studies have either been of insufficient duration to observe changes in HbA1c, as the standard measure of glycemic control, or have been underpowered. Therefore, more long-term clinical trials are required to examine the role of nuts on glycemic control in patients with prediabetes and diabetes. Overall, there are good reasons to justify further exploration of the use of nuts in the prevention of diabetes and its microand macrovascular complications.

Nuts, inflammation and insulin resistance

Casas-Agustench, P., M. Bulló, J. Salas-Salvadó, 2010. Nuts, inflammation and insulin resistance. Asia Pac J Clin Nutr. 19(1):124-130.

The beneficial effects of nut consumption on cardiovascular disease (CVD) have been widely documented. These protective effects are mainly attributed to the role of nuts in the metabolism of lipids and lipoproteins. As chronic inflammation is a key early stage in the atherosclerotic process that predicts future CVD events and is closely related to the pathogenesis of insulin resistance, many recent studies have focused on the potential effect of nut consumption on inflammation and insulin resistance. Through different mechanisms, some components of nuts such as magnesium, fiber, α-linolenic acid, L-arginine, antioxidants and MUFA may protect against inflammation and insulin resistance. This review evaluates the epidemiologic and experimental evidence in humans demonstrating an association between nut consumption and these two emergent cardio-protective mechanisms.

Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome

Casas-Agustench, P., P. Lopez-Uriarte, M. Bullo’, E. Ros, J.J. Cabre’-Vila, J. Salas-Salvado’, 2009. Effects of one serving of mixed nuts on serum lipids, insulin resistance and inflammatory markers in patients with the metabolic syndrome. Nutrition, Metabolism & Cardiovascular Diseases. doi:10.1016/j.numecd.2009.08.005.

Background and aims: Knowledge of the effect of nut consumption on metabolic syndrome (MetS) components is limited. We assessed the effects of nut intake on adiposity, serum lipids, insulin resistance, and inflammatory biomarkers in patients with MetS. Methods and results: In a randomized, parallel-group, 12-week feeding trial, 50 patients with MetS were given recommendations for a healthy diet with or without supplementation with 30 g/day of raw nuts (15 g walnuts, 7.5 g almonds and 7.5 g hazelnuts) (Nut and Control diet groups, respectively). Adiposity measures, serum lipids, insulin, Homeostasis Model Assessment (HOMA), interleukin-6 (IL-6) and other inflammatory biomarkers, and 48-h fecal fat were determined basally and at study’s completion. Moderate weight loss, decreased adiposity, and lower blood pressure occurred similarly after both diets. The Control, but not the Nut diet, was associated with significant (P < 0.05) reduction of LDL-cholesterol, with mean changes of -0.36 versus -0.13 mmol/L, respectively (between-group differences, P=0.154). The Nut diet reduced fasting insulin by 2.60 µU/mL (95% CI, -4.62 to -0.59) and HOMA-insulin resistance by 0.72 (-1.28 to -0.16) (P < 0.05 versus Control diet; both). Among inflammatory markers, the Nut diet resulted in changes of median plasma IL-6 of -1.1 ng/L (-2.7 to -0.1; P=0.035 versus Control diet), but adjustment for weight loss attenuated the significance of the association. Stool fat decreased with the Control diet and slightly increased with the Nut diet (P < 0.05 for between-group differences). Conclusion: Patients with MetS show decreased lipid responsiveness but improved insulin sensitivity after daily intake of 30 g of mixed nuts.

Regular consumption of nuts is associated with a lower risk of cardiovascular disease in women with type 2 diabetes

Li, T.Y., A.M. Brennan, N.M. Wedick, C. Mantzoros, N. Rifai, F.B. Hu, 2009. Regular Consumption of Nuts Is Associated with a Lower Risk of Cardiovascular Disease in Women with Type 2 Diabetes. J. Nutr.139:1333-1338.

Higher nut consumption has been associated with lower risk of coronary heart disease (CHD) events in several epidemiologic studies. The study examined the association between intake of nuts and incident cardiovascular disease (CVD) in a cohort of women with type 2 diabetes. For the primary analysis, there were 6309 women with type 2 diabetes who completed a validated FFQ every 2-4 y between 1980 and 2002 and were without CVD or cancer at study entry. Major CVD events included incident myocardial infarction (MI), revascularization, and stroke. During 54,656 person-years of follow-up, there were 452 CHD events (including MI and revascularization) and 182 incident stroke cases. Frequent nut and peanut butter consumption was inversely associated with total CVD risk in age-adjusted analyses. After adjustment for conventional CVD risk factors, consumption of at least 5 servings/wk of nuts or peanut butter [serving size, 28 g (1 ounce) for nuts and 16 g (1 tablespoon) for peanut butter] was significantly associated with a lower risk of CVD (relative risk = 0.56; 95% CI: 0.36-0.89). Furthermore, when we evaluated plasma lipid and inflammatory biomarkers, we observed that increasing nut consumption was significantly associated with a more favorable plasma lipid profile, including lower LDL cholesterol, non-HDL cholesterol, total cholesterol, and apolipoprotein-B-100 concentrations. However, we did not observe significant associations for HDL cholesterol or inflammatory markers. These data suggest that frequent nut and peanut butter consumption is associated with a significantly lower CVD risk in women with type 2 diabetes.